Ships within 24 hours on business days · +10% with Bank Pay

SS-31 (Elamipretide)

Shop

SS-31 (Elamipretide) · Research brief

SS-31 Elamipretide: History and Discovery Timeline

52 WORDS

Short answer

The SS-31 elamipretide history discovery narrative begins not with mitochondria but with opioid peptide chemistry. The tetrapeptide now catalogued as SS-31, and later given the international nonproprietary name elamipretide, was synthesized as one member of a numbered series of small aromatic-cationic peptides that had originally been designed around a different pharmacological question.

The SS-31 elamipretide history discovery narrative begins not with mitochondria but with opioid peptide chemistry. The tetrapeptide now catalogued as SS-31, and later given the international nonproprietary name elamipretide, was synthesized as one member of a numbered series of small aromatic-cationic peptides that had originally been designed around a different pharmacological question. The mitochondrial behaviour of the series, that these peptides cross cell membranes without a transporter and concentrate in the inner mitochondrial membrane, was described by the originating laboratories as an unexpected observation rather than a design goal. From that observation the series was redirected: through in vitro oxidant-challenge work in the early 2000s, through organ ischemia and reperfusion models later that decade, through a published reframing of the mechanism around the inner-membrane phospholipid cardiolipin in the early 2010s, and then into an industrial development program that carried the compound under several different names. This page covers that chronology only. Mechanism detail and current trial status are handled separately, and nothing here is guidance for use of any kind.

What is SS-31, and where does the name come from?

SS-31 is a synthetic tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2, where Dmt is 2',6'-dimethyltyrosine and the C-terminus is amidated. The 'SS' prefix is an initialism drawn from the surnames of the two investigators whose laboratories co-developed the series, and the number refers to the position of that analog within the numbered set of compounds the collaboration synthesized and screened. The literature therefore refers to a family of related molecules, SS-01, SS-02, SS-19, SS-20, SS-31 and others, rather than to a single isolated compound, and comparisons between members of the series are an important part of how the pharmacology was worked out.

The same molecule later acquired an international nonproprietary name, elamipretide, along with a development code used by the company that took the program forward. Research catalogs and the published literature therefore use several labels interchangeably. Real Peptides lists the compound under the combined designation at SS-31 (elamipretide) and maintains a broader SS-31 reference hub for related research questions.

For anyone reading backwards through the literature, the naming matters practically. Papers from the mid-2000s almost always say SS-31 or refer to the series by prefix. Papers from the mid-2010s onward increasingly say elamipretide. A literature search run on only one of those strings will miss a substantial part of the record. The same caution applies to procurement: verifying a compound's CAS number and molecular identity against the certificate of analysis for the specific lot, rather than relying on the trade-style name alone, is the standard way a laboratory confirms that the material in hand is the molecule described in the papers being replicated.

Which research program did the SS peptide series originate from?

The series came out of opioid peptide chemistry, not out of mitochondrial biology. The structural starting point was a small, highly cationic analog of a naturally occurring amphibian opioid peptide, a tetrapeptide amide carrying a tyrosine at position one and a D-arginine at position two. Substituting the N-terminal tyrosine with 2',6'-dimethyltyrosine, a non-standard aromatic residue that chemists had shown increases affinity at the mu-opioid receptor, produced a markedly more potent analog. That analog, catalogued within the series as an early SS number, was the practical origin of everything that followed.

The research question at that stage concerned peptide analgesia and, in particular, whether a highly charged peptide could be made to act usefully without crossing the blood-brain barrier. Charge was the design feature of interest, because multiple positive charges were expected to limit passive diffusion across membranes. The early work on the series was accordingly concerned with receptor affinity, metabolic stability conferred by D-amino acid substitution, and the distribution behaviour of a small, polycationic, protease-resistant peptide.

That framing is the reason the later discovery is usually described in the literature as serendipitous. A molecule designed around the expectation of poor membrane penetration turned out to enter cells readily. Reviews written from within the originating program, including First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics (British Journal of Pharmacology, 2014), narrate the sequence in those terms and treat the uptake finding as the pivot point of the program. That review is a useful chronological source precisely because it is a retrospective account, but it is also an account written by the originators, so its framing of significance should be read as interpretation rather than as independent assessment.

How was the mitochondrial localization of the SS peptides discovered?

The mitochondrial behaviour was identified in cell-uptake experiments, not predicted from the structure. When fluorophore-labelled analogs of the series were applied to cultured cells, the peptides were found inside the cells rather than excluded at the membrane, and the intracellular signal was reported to concentrate in mitochondria rather than distributing evenly through the cytosol. Follow-up work described the uptake as rapid, as occurring in multiple cell types, and as not requiring a specific transporter.

Two features of that observation drove the reorientation of the program. The first was the localization itself: a small peptide that accumulates in the inner mitochondrial membrane is, in principle, a vehicle for delivering chemistry to the site where oxidative phosphorylation and much of cellular reactive oxygen species handling occur. The second was that the accumulation was described as not being driven by the mitochondrial membrane potential, which distinguished the series from lipophilic cation approaches such as triphenylphosphonium conjugates, whose accumulation depends on a polarized membrane. Research in this area suggests that the distinction has practical consequences for depolarized or injured mitochondria, where potential-driven accumulation is expected to fall away.

The limits of the original observation deserve to be stated plainly. Much of the early localization work used labelled analogs, and a fluorophore is a substantial chemical addition to a four-residue peptide, so the labelled molecule is not strictly identical to the unlabelled one. The experiments were in cultured cells, which do not reproduce the distribution of a compound across a whole organism. And localization alone does not establish that a compound does anything functionally useful once it arrives. The decade of work that followed can be read as an effort to close those three gaps.

What structural features define SS-31, and why is it not an opioid agonist?

SS-31 keeps the motif that defines the series, alternating aromatic and basic residues in a short amidated tetrapeptide, but rearranges it so that the dimethyltyrosine sits at position two rather than position one. The sequence is D-Arg-Dmt-Lys-Phe-NH2. The literature describes this residue order as the reason the compound does not carry the mu-opioid activity of the earlier analogs in the series, since N-terminal tyrosine or dimethyltyrosine is the pharmacophore element those receptors require. Separating the mitochondrial behaviour from receptor pharmacology was a deliberate medicinal-chemistry step, and it is the single change that made the later development program coherent.

Other structural choices follow the same logic. The D-arginine and the amidated C-terminus both reduce susceptibility to peptidase cleavage relative to an all-L, free-acid peptide, which matters for any work outside a buffer. The net positive charge at physiological pH, contributed by the arginine and lysine side chains, is thought to drive association with the anionic head groups of inner-membrane phospholipids. The dimethyltyrosine contributes a phenolic hydroxyl, which was the basis for the original description of the compound as a scavenger of reactive species, and that phenol is also what made the comparison with non-phenolic analogs of the series so informative later.

Researchers reading structure-activity sections of the older papers will find frequent reference to analogs that differ by one residue. The value of those comparisons is that they allow mechanistic claims to be tested within a closely related chemical set rather than against unrelated compounds. The limit is that the analogs were developed and compared largely within one program, so the structure-activity picture reflects the set of molecules that program chose to make.

What did the earliest published studies on SS-31 report?

The first wave of published work, from the early to mid-2000s, was mostly in vitro and ex vivo. Studies report that cells exposed to oxidant challenge showed less reactive oxygen species accumulation and less cell death in the presence of the peptide, that isolated mitochondria showed less swelling under calcium or oxidant stress, and that isolated perfused organ preparations subjected to oxygen and nutrient deprivation followed by restoration recovered contractile or metabolic function more completely in the exposed arms. The language of those early reports is the language of mitochondria-targeted antioxidants, and that is how the series was classified for roughly a decade.

Several limits are worth carrying forward when reading that literature today. Oxidant-challenge models are deliberately severe and are not models of any chronic condition. Isolated mitochondria behave differently from mitochondria embedded in an intact cell with its own antioxidant and repair systems. Ex vivo perfused organs lack circulating immune cells and neurohormonal input. And because the reactive-species readouts of that era often depended on fluorescent probes with known specificity problems, a reported reduction in probe signal is weaker evidence than it can appear to be at first reading.

The broader historical point is that the early evidence base was coherent but narrow: short-duration protection against acute oxidative insult, in reductionist preparations, measured largely by probes and by structural endpoints such as swelling. That narrowness is exactly what the next phase of the program set out to widen, by moving into whole-animal ischemia and reperfusion models where functional and biochemical endpoints could be measured in an intact organism.

How did ischemia and reperfusion research shape the development path?

Ischemia and reperfusion models became the central preclinical platform for the series during the late 2000s and early 2010s, because they combine an abrupt bioenergetic collapse with a well-described burst of oxidative stress on restoration of flow. One of the clearer examples in the record is Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury (Journal of the American Society of Nephrology, 2011), which reports that in a rodent renal ischemia and reperfusion model the exposed arms showed faster recovery of adenosine triphosphate after flow was restored, better preservation of mitochondrial ultrastructure in the early reperfusion window, and reduced markers of tubular injury compared with controls.

Two features of that work pushed the program forward. The first was the speed of the effect: recovery differences were observed early after reperfusion rather than only at late time points, which is hard to reconcile with a mechanism that depends on changes in gene expression and easier to reconcile with a direct physical effect on the inner membrane. The second was that structural preservation of cristae tracked with the functional recovery, which pointed attention toward membrane architecture rather than toward bulk radical scavenging alone.

The limits are those of the model class. Rodent ischemia and reperfusion studies use a controlled, timed insult in otherwise healthy young animals, with the compound present at or before reperfusion, and they measure outcomes over hours to days. They are informative about acute mitochondrial rescue and far less informative about chronic exposure, aged or comorbid physiology, or any outcome measured in months. Anyone treating this phase of the record as evidence for durable effects is reading more into it than the designs support.

When and why did the proposed mechanism shift from radical scavenging to cardiolipin interaction?

The reframing is usually dated to the early 2010s, and its clearest published expression is The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin (Journal of the American Society of Nephrology, 2013). That work describes selective association of the peptide with cardiolipin, the signature phospholipid of the inner mitochondrial membrane, and argues that this association, rather than free-radical scavenging, accounts for the preservation of cristae structure and the recovery of electron transport observed in ischemic preparations. The proposed consequence is that cardiolipin-bound cytochrome c retains its electron-carrier function instead of shifting toward peroxidase activity, which the literature links to cristae remodelling and to the release of pro-apoptotic signals.

Two lines of internal evidence made the shift persuasive within the field. One was the comparison between series members that carry the dimethyltyrosine phenol and members that do not: analogs lacking that residue, and therefore lacking the proposed scavenging chemistry, were still reported to be protective in several preparations, which is difficult to explain if scavenging is the primary mechanism. The other was the association of the effect with membrane architecture and with the kinetics of recovery rather than with downstream antioxidant gene programs.

The British Journal of Pharmacology review cited above consolidated this reading and introduced the cardiolipin-protective framing that the industrial program subsequently used. The honest limit is that mechanism in this field is inferred from a convergence of biophysical, structural and functional observations rather than demonstrated by a single decisive experiment, and that much of the convergent evidence came from one research lineage. Independent replication across laboratories, models and readouts is what would strengthen it, and evaluating how far that has happened is a question for a mechanism-focused review rather than for a chronology.

How did SS-31 move from academic laboratories into industrial development?

The transition followed the familiar route for an academic small-molecule or peptide asset: institutional patenting of the series, licensing to a company formed around the technology, and re-coding of the lead compound under a corporate development designation. Public development records associate the elamipretide program with Stealth BioTherapeutics, which carried the compound through preclinical expansion and into clinical study. During the cardiovascular phase of that work the molecule appeared in the literature and in conference reporting under a company code and under a development-era brand-style name, and only later under the nonproprietary name elamipretide.

What changed on moving into industry was mainly scale and breadth rather than mechanism. The compound was supplied to many external academic groups, which produced a scattered preclinical literature across organ systems and species during the 2010s, written by investigators with no connection to the originating laboratories. For a reader reconstructing the history, that external literature is valuable because it is where independent handling of the compound begins, and because it is where negative or equivocal results are more likely to be reported.

The limits of this period in the record are practical. Industrial programs publish selectively and on their own timeline, so the published preclinical record is not a complete account of what was run. Material supplied to collaborators varies in salt form and in characterization detail between sources, and older papers do not always state which. And a development code appearing in a paper title does not by itself indicate the stage or the outcome of any program. This page deliberately stops short of reporting clinical program status, which belongs on a separate page and which changes over time.

Why does one compound carry four different names?

Because each name belongs to a different stage of the chronology. SS-31 is the laboratory series designation from the discovery phase and remains the string most used in preclinical papers. The corporate development code was assigned when the asset moved into company hands. A brand-style development name was used during the cardiovascular phase of the clinical program. Elamipretide is the international nonproprietary name, assigned through the formal naming process that gives a single pharmacological agent one globally recognized generic identifier, and it is the string that dominates the later literature and regulatory record.

This matters for literature work. A systematic search of the compound's history that uses only one identifier will produce a biased slice of the record, typically either the preclinical mechanism literature or the clinical-era literature but not both. Searching all known identifiers, including the series designation with and without the hyphen, is the straightforward correction.

It also matters for procurement and for reproducibility. Research-grade material may be listed under the series designation, under the nonproprietary name, or under both, and the name alone does not confirm molecular identity. The verifiable checks are the stated sequence, the CAS number, and lot-specific analytical documentation. Real Peptides publishes independent third-party certificates of analysis for every batch at /coas/, and supplies the compound strictly as a research-use-only material through the catalog. Matching the identity information on a certificate against the molecule described in the papers being replicated is the step that keeps a literature comparison meaningful.

How did the indication focus of the program change over time?

The preclinical and development focus moved, broadly, from acute organ protection toward chronic and genetic mitochondrial dysfunction. The earliest in vivo emphasis was on ischemia and reperfusion in heart and kidney, which suited a mechanism described as rescuing bioenergetics during an acute insult. Over the 2010s the published emphasis widened toward conditions where mitochondrial structure and function are impaired continuously rather than transiently, including rare inherited mitochondrial disorders, skeletal muscle function, and ophthalmic tissue, where photoreceptors and retinal pigment epithelium are among the most mitochondria-dense tissues in the body.

The logic of that migration is visible in the mechanism history. If the compound acts by associating with cardiolipin and stabilizing cristae architecture, then settings defined by abnormal cardiolipin handling or by chronically disordered inner-membrane structure are the settings where an effect would be most expected. That reasoning, rather than any single decisive result, appears to have shaped the sequence of programs.

This page does not report the status or the outcomes of any clinical program, and readers should not infer either from the fact that an indication was pursued. Development programs proceed and stop for many reasons, including trial design, endpoint selection and commercial considerations, and the public record changes. For anyone tracking that dimension, the appropriate sources are the trial registries and the agency records themselves, read at the time of the query rather than from a secondary summary. The historical point here is narrower and more durable: the indication map of this compound followed the mechanism reframing rather than preceding it.

What did aging and skeletal muscle research add to the record?

From the early 2010s onward a distinct strand of academic literature examined the series in the context of aged tissue, particularly skeletal muscle and heart, on the rationale that mitochondrial function, cristae structure and cardiolipin composition all change with age. Studies in this strand generally report measures of mitochondrial respiration, of phosphocreatine recovery kinetics as an in vivo proxy for oxidative capacity, and of muscle performance in aged animals compared with younger controls and with unexposed aged controls. Research suggests the compound can shift some of these measures in aged rodent tissue, and that is how the aging literature on this molecule is usually summarized.

The interpretive cautions here are significant. Aged-rodent work uses a small number of inbred strains under controlled housing and feeding, which compresses the variability that characterizes aging in free-living populations. Functional endpoints such as grip or treadmill performance are influenced by motivation and handling as well as by muscle bioenergetics. Short exposure windows in old animals test reversibility of an existing deficit, not prevention over a lifespan, and the two questions require different designs. And readouts of mitochondrial respiration in permeabilized fibres or isolated mitochondria do not automatically translate into whole-organism capacity.

This strand is nonetheless historically important for one reason: it is where the compound was handled most widely by laboratories outside the originating program and the development company, and where comparisons against other mitochondria-directed approaches began to appear. For a discovery-and-development history, that diffusion into independent hands is as meaningful a milestone as any single result.

What are the main limits of the historical evidence base?

Four limits recur across the whole chronology and are worth stating together. First, lineage concentration: a large share of the foundational mechanistic work, and most of the retrospective narrative accounts, come from the originating program or from close collaborators. That does not make the work wrong, but it means the framing of significance has not been independently constructed. Second, model selectivity: the in vivo record is dominated by acute insult models in young rodents, which are informative about rescue from a defined injury and weak evidence for anything chronic.

Third, mechanism inference: the cardiolipin-association account is a synthesis of biophysical binding data, structural observations and functional rescue, not the output of a single definitive experiment, and alternative or additional contributions have not been excluded. Earlier literature on the same compound used an antioxidant framing with comparable confidence, which is itself a reminder of how mechanistic consensus can move. Fourth, nomenclature and material heterogeneity: identifiers changed over two decades, salt forms and characterization practices varied between suppliers and eras, and older papers often do not record those details, which complicates cross-study comparison.

None of this makes the history unusable. It makes it a history that should be read with its scaffolding visible: an accidental localization finding, a decade of acute-injury pharmacology, a mechanism reframing that reorganized the field's interpretation of earlier data, and a development program that broadened the compound's exposure to independent laboratories. Treating any one phase as the settled account of the molecule misreads the record.

How should researchers read this chronology when planning laboratory work?

As context for study design and for literature retrieval, not as a protocol. The practical reading is that the published record splits into eras with different vocabularies, different endpoints and different standards of evidence, and that any new in vitro or preclinical comparison needs to be explicit about which era it is engaging with. A study framed against the antioxidant literature of the 2000s will choose different readouts from one framed against the cardiolipin and cristae literature of the 2010s, and the two are not interchangeable.

Retrieval practice follows from the naming history: search the series designation and the nonproprietary name together, include the hyphenated and unhyphenated forms, and expect the clinical-era and preclinical-era literatures to surface under different strings. Reporting practice follows from the material heterogeneity: stating the identifier used, the sequence, the source and the lot-specific analytical documentation in a methods section is what allows another laboratory to reproduce the comparison.

Real Peptides does not provide preparation, handling or use guidance for any catalog compound, because these are research-use-only materials intended for qualified laboratories that set their own documented procedures under institutional oversight.

How does Real Peptides supply SS-31 for laboratory research?

Real Peptides supplies SS-31, also listed as elamipretide, as a research-use-only compound for laboratory and institutional buyers, and publishes an independent third-party certificate of analysis for every batch. The compound page sits at SS-31 (elamipretide), the wider reference material at the SS-31 hub, the full catalog at /shop/, and the lot documentation at /coas/. Shipping and operating details are listed on the location page.

The supplier-side checks that matter for a compound with this naming history are straightforward and verifiable: confirm that the listed identity, including sequence and CAS number, matches the molecule described in the literature being replicated; confirm that the certificate of analysis provided corresponds to the specific lot received rather than to a generic reference document; and record those identifiers in the methods section of any resulting work. Independent third-party testing of every batch and publicly accessible certificates are what make those checks possible rather than nominal.

Nothing on this page is guidance for use in humans or animals outside a properly approved research setting, and nothing here describes preparation, quantity selection or handling for any living subject. The history above is offered as a research brief: the origin of the series in opioid peptide chemistry, the unexpected mitochondrial localization that redirected it, the acute-injury pharmacology that built the preclinical case, the cardiolipin reframing that reorganized the mechanism, and the industrial phase that gave the molecule its later names. Current development status and detailed mechanism are covered separately.

All compounds discussed on this page are sold for laboratory research use only and are not for human consumption.

References

  • Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury. Journal of the American Society of Nephrology. 2011. PMID: 21546574. pubmed.ncbi.nlm.nih.gov/21546574
  • The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology. 2013. PMID: 23813215. pubmed.ncbi.nlm.nih.gov/23813215
  • First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology. 2014. PMID: 24117165. pubmed.ncbi.nlm.nih.gov/24117165

Questions

SS-31 came out of an academic collaboration between two laboratories working on opioid peptide chemistry, with the series developed through the late 1990s and the mitochondrial findings published from the early 2000s onward. The 'SS' prefix is an initialism of the two investigators' surnames, and 31 marks the analog's place in the synthesis series.
Yes. SS-31 is the original laboratory series designation and elamipretide is the international nonproprietary name assigned later, with a corporate development code and a development-era brand-style name also appearing in the record. All refer to the same tetrapeptide, D-Arg-Dmt-Lys-Phe-NH2, so literature searches should include every identifier.
Because the series was designed around opioid receptor chemistry and high positive charge, which was expected to limit membrane penetration. Cell-uptake experiments instead showed the peptides entering cells readily and concentrating in mitochondria. That unanticipated localization, rather than any original design goal, redirected the entire research program toward mitochondrial biology.
Early work emphasized the dimethyltyrosine phenol as a radical-scavenging element. Later studies reported that series members lacking that residue remained protective, and that the compound associates selectively with cardiolipin in the inner mitochondrial membrane. The literature reframed the mechanism around membrane and cristae stabilization rather than bulk scavenging.
The literature reports that it does not. The earlier analogs carried dimethyltyrosine at position one, which supplies the mu-opioid pharmacophore. SS-31 places dimethyltyrosine at position two instead, a deliberate medicinal-chemistry change described as separating the mitochondrial behaviour of the series from receptor-mediated opioid activity.
The foundational in vivo work used acute ischemia and reperfusion models, including a rodent renal model reported in the Journal of the American Society of Nephrology in 2011, alongside isolated mitochondria and ex vivo perfused organ preparations. These designs test rescue from a timed acute insult and say little about chronic exposure or aged physiology.
No. This page is a discovery and development chronology only, and clinical program status changes over time. Trial registries and regulatory agency records, consulted at the time of the question, are the appropriate primary sources. Mechanism detail is also covered separately from this historical account.
By checking the stated sequence and CAS number against the published molecule, and by reviewing the certificate of analysis issued for the specific lot received rather than a generic document. Real Peptides publishes independent third-party certificates for every batch, which makes that identity check verifiable rather than nominal.
No. Real Peptides supplies research-use-only compounds and does not provide preparation or use guidance of any kind. Qualified laboratories set their own documented procedures under institutional oversight. The only measurement framework described here is concentration, expressed as milligrams per millilitre, with per-assay quantities in micrograms.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA

Shop Now